DALLAS, Sept. 27, 2004 (PRIMEZONE) -- TalkingStocks.com has issued an `Attractive' rating for Biophan Technologies (OTCBB: BIPH), a cutting-edge developer of next-generation biotechnologies.
In the report, Jeff Bishop, Senior Investment Analyst for TalkingStocks.com, discusses at length his outlook for the company. Mr. Bishop shares this comment about Biophan, "We believe that in the coming months, the market will gradually digest the company's news and see the true value of its products. Investors who are willing to take the time to understand this remarkable company and invest in it early should see significant returns as the company gains favor on Wall Street." He later adds, "The company's strategy of using joint ventures, such as that with Boston Scientific (NYSE:BSX), will most likely create win-win opportunities for both firms."
The report can be viewed in its entirety on TalkingStocks.com, or by clicking the link below:
http://www.talkingstocks.com/reports/BIPH_092704.php
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with magnetic resonance imaging (MRI) equipment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create enhanced MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan product lines include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors have 20 issued U.S. patents and 72 patents pending, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.
About TalkingStocks.com
TalkingStocks.com is a leading Internet stock investment web site providing coverage and analysis of many up-and-coming firms. TalkingStocks.com is associated with Stockguru.com. Both offer profiles and interviews with key executives from publicly traded companies. For more information on TalkingStocks.com, contact John Pentony, 972-731-8621, Publisher@stockguru.com.
Disclosure: TalkingStocks.com has been compensated $3000 for coverage.
Cautionary Language
Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. Further, the Company operates in industries where securities values may be volatile and may be influenced by regulatory and other factors beyond the Company's control. Other important factors that the Company believes might cause such differences are discussed in the risk factors detailed in the Company's 10-KSB and its quarterly reports on Form 10-QSB both as filed with the Securities and Exchange Commission, which include the Company's cash flow difficulties, dependence on significant customers, and rapid development of technology, among other risks. In assessing forward-looking statements contained herein, readers are urged to carefully read all cautionary statements contained in the Company's filings with the Securities and Exchange Commission.